Financial Trade Freedom - Investing and Stock News
  • Investing
  • News
  • Editor’s Pick
  • Economy
  • Stock
  • Investing
  • News
  • Editor’s Pick
  • Economy
  • Stock
No Result
View All Result
Financial Trade Freedom - Investing and Stock News
No Result
View All Result
Home Investing

Bayer share price is rising: does it have more upside?

admin by admin
June 26, 2025
in Investing
0
Bayer share price is rising: does it have more upside?
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Bayer share price has bounced back this year, making it one of the best-performing companies in the German DAX Index. It has jumped to €26, up by 45% from its lowest point this year. It remains 75% below its all-time high, which it got to in 2025. 

Why Bayer share price has jumped

Bayer stock price has rallied recently after the company published encouraging results last month. Its numbers were better than expected, helped by its cancer and kidney business, which helped to offset a big drop in agricultural sales. 

The data showed that its adjusted earnings came in at €4.09 billion in the first quarter. While this was a big drop from what it made last year, it was higher than the median estimate of €3.8 billion. 

Bayer’s sales dropped slightly to €13.7 billion last quarter, with its crops division falling by 4.1% to €7.9 billion. This decline happened as farmers reduced their spending as commodity prices fell. 

Bayer’s pharmaceutical segment grew by 4.4% to €4.35 billion, with its earnings before interest, tax, depreciation, and amortization (EBITDA) rising by over 11% to over €1 billion. 

Bayer’s consumer health’s revenue also jumped by 4.7% last quarter to €1.4 billio, with its EBITDA soaring by 3.7% to €322 million. 

Its stock also jumped as the company continued its cost-cutting measures and confirmed its forward guidance. It ended the quarter with over 90,880 employees, down by 7.4% from the same period last year. This decline helped to reduce its employee-related expenses by 0.4% to €3.02 billion. 

In total, the company slashed workers by 2,000 in the first quarter, and has now shed over 11,000 since its turnaround started. 

Bayer stock price has also jumped as the company continued to prioritize its debt, most of which came from its Monsanto acquisition. As part of this approach, the company has largely paused making large buyouts this year. It ended the last quarter with over €38 billion in total debt. 

Challenges remain

While Bayer share price has rebounded, analysts believe that it faces more challenges ahead. The biggest challenge is that its crop science business is not expected to return to growth this year, now that most agricultural commodities have plunged. 

Donald Trump’s tariffs could impact the company on imported goods since the US is one of its top markets. In its recent statement, the company anticipated that its sales will be between €44.5 billion and €46.5 billion, with its EBITDA falling again to between €9.2 billion and €9.7 billion.

A key aspect to note is that the company is also highly exposed to the strong euro, which has jumped to the highest level in years.

The other challenge is that the Roundup crisis continues. It has set aside about €16 billion to handle the claims, and has already paid €10 billion of it. Analysts are optimistic that the company will move forward once the crisis ends. An HSBC analyst said:

“Once the litigation overhang is cleared, the company may be better able to present a strategy to shareholders to de-gear the balance sheet, which could enable it to invest in its pharma pipeline.”

Bayer stock price analysis

Bayer share price chart | Source: TradingView

The daily chart shows that the Bayer share price bottomed at €18.20 and formed a double-bottom pattern. It has now moved above the neckline at €25.32, the highest swing on March 5.

Bayer stock has also formed a bullish flag pattern, a popular bullish sign in technical analysis. It has also formed a golden cross as the 50-day and 200-day moving averages have crossed each other. 

Therefore, the stock will likely have a bullish breakout, with the next point to watch being at €30, up by 16% above the current level. A move above that level will point to more gains, potentially to €50.

The post Bayer share price is rising: does it have more upside? appeared first on Invezz


Previous Post

SMCI stock price analysis as Supermicro forms risky H&S pattern

Next Post

Here’s why the top DAX Index stocks of 2025 are rising

Next Post
Here’s why the top DAX Index stocks of 2025 are rising

Here’s why the top DAX Index stocks of 2025 are rising

  • Trending
  • Comments
  • Latest
U.S. homebuilders raise alarm over tariffs as sentiment falls to 5-month low

U.S. homebuilders raise alarm over tariffs as sentiment falls to 5-month low

February 19, 2025
How Companies Use Derivatives To Hedge Risk

How Companies Use Derivatives To Hedge Risk

February 19, 2025
KFC moves U.S. headquarters from Kentucky to Texas

KFC moves U.S. headquarters from Kentucky to Texas

February 19, 2025
Nvidia shares continue golden run, hit fresh highs: analysts remain firmly bullish

Nvidia shares continue golden run, hit fresh highs: analysts remain firmly bullish

June 27, 2025
Lucid stock price forms descending triangle ahead of earnings

Lucid stock price forms descending triangle ahead of earnings

0
From tariffs to DOGE, what companies are saying about the impact of MAGA policies

From tariffs to DOGE, what companies are saying about the impact of MAGA policies

0
Tesla’s law firm drafts Delaware bill that could salvage Musk pay package

Tesla’s law firm drafts Delaware bill that could salvage Musk pay package

0
Coca-Cola takes on Olipop and Poppi with new prebiotic soda brand, Simply Pop

Coca-Cola takes on Olipop and Poppi with new prebiotic soda brand, Simply Pop

0
Lucid stock price forms descending triangle ahead of earnings

Lucid stock price forms descending triangle ahead of earnings

July 9, 2025
China’s AI gamble: 115,000 Nvidia chips at heart of geopolitical tech clash

China’s AI gamble: 115,000 Nvidia chips at heart of geopolitical tech clash

July 9, 2025
Linda Yaccarino resigns as X CEO following Grok  controversy

Linda Yaccarino resigns as X CEO following Grok controversy

July 9, 2025
Brazil’s Braskem shares surge on prospects of tax incentive bill backing petrochemical sector

Brazil’s Braskem shares surge on prospects of tax incentive bill backing petrochemical sector

July 9, 2025

    Get Smarter with Your Money – Sign Up for Free Financial Tips!


    Join our community of savvy savers and investors! By signing up, you'll receive weekly emails packed with personalized financial tips, budgeting hacks, and investment strategies tailored to your income level. Take control of your finances today – it’s free and only takes a minute!

    Recent News

    Lucid stock price forms descending triangle ahead of earnings

    Lucid stock price forms descending triangle ahead of earnings

    July 9, 2025
    China’s AI gamble: 115,000 Nvidia chips at heart of geopolitical tech clash

    China’s AI gamble: 115,000 Nvidia chips at heart of geopolitical tech clash

    July 9, 2025
    Linda Yaccarino resigns as X CEO following Grok  controversy

    Linda Yaccarino resigns as X CEO following Grok controversy

    July 9, 2025
    Brazil’s Braskem shares surge on prospects of tax incentive bill backing petrochemical sector

    Brazil’s Braskem shares surge on prospects of tax incentive bill backing petrochemical sector

    July 9, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Disclaimer: FinancialTradeFreedom.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 financialtradefreedom.com | All Rights Reserved

    No Result
    View All Result
    • About us
    • Contacts
    • Email Whitelisting
    • Investing and Stock News
    • Privacy Policy
    • Terms and Conditions
    • Thank you

    Disclaimer: FinancialTradeFreedom.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 financialtradefreedom.com | All Rights Reserved